Blood

Vol. 148, Issue 3 Issue 3 2026
17
Articles

Articles in this Issue

The fellowship of the ring: TMEM187 guides iron to heme

Yvette Y. Yien Jul 16, 2026 pp. 271-272 10.1182/blood.2026033658

Blinatumomab consolidation for high-risk Ph− B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study

Nicolas Boissel, Françoise Huguet, Thibaut Leguay et al. Jul 16, 2026 pp. 289-299 10.1182/blood.2026033309

Abstract Intensified chemotherapy regimens have improved outcomes in adults with Philadelphia chromosome–negative (Ph−) B-cell acute lymphoblastic leukemia (B-ALL), yet relapse rem...

Oxidized PDI promotes thrombus formation in oxidative stress

Moua Yang, Osamede C. Owegie, Anika Patel et al. Jul 16, 2026 pp. 376-388 10.1182/blood.2025031756

Abstract Protein disulfide isomerase (PDI) functions in thrombus formation in vivo and represents a viable target for antithrombotic therapy. PDI is a redox sensor that can either...

A QUEST to improve outcomes for adults with high-risk B-ALL

Hrishikesh K. Srinagesh, Lori S. Muffly Jul 16, 2026 pp. 265-266 10.1182/blood.2026034249

TMEM187 is a novel brakelike modulator in the regulation of erythropoiesis

Yutong Liu, Wenxin Zhang, Jing Cai et al. Jul 16, 2026 pp. 361-375 10.1182/blood.2025031135

Abstract Erythropoiesis, the process of red blood cell production, is highly dependent on iron uptake by transferrin and its receptor, transferrin receptor 1 (TfR1). However, the m...

Bollard CM, Heslop HE. A reassessment of anti–CAR T-cell expansion strategies. <i>Blood</i> . 2026;147(22):2561-2562.

Jul 16, 2026 pp. 389-389 10.1182/blood.2026035263

Crossing the trial-practice chasm in CAR-T for relapsed LBCL

Manali Kamdar Jul 16, 2026 pp. 269-271 10.1182/blood.2026033662

Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas)

Gaurav Goyal, Oussama Abla, John Chan et al. Jul 16, 2026 pp. 275-288 10.1182/blood.2026033049

Abstract Malignant histiocytic neoplasms (MHNs) are rare tumors derived from the mononuclear phagocyte system (MPS), encompassing histiocytic sarcoma, Langerhans cell sarcoma, inte...

Deregulation of <i>FOXF1</i> / <i>FENDRR</i> from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia

Danika Di Giacomo, Petri Pölönen, Valentina Bardelli et al. Jul 16, 2026 pp. 317-334 10.1182/blood.2025031402

Abstract Despite great progress in understanding the genomic basis of immature T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL) and acute leukemias of ambiguous l...

<i>BCL11B</i> enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL

Kaito Mimura, Akira Kaino, Yotaro Ochi et al. Jul 16, 2026 pp. 335-347 10.1182/blood.2025031466

Abstract The molecular classification of T-cell acute lymphoblastic leukemia (T-ALL) remains incomplete, limiting risk stratification and the development of targeted therapies. Enh...

Maternal anti-HPA-1a antibodies block αIIbβ3/αvβ3 integrin activation, and blockade correlates with FNAIT disease severity

Wendy Stam, Jeremy D. Broekhuis, Femke W. T. van der Meer et al. Jul 16, 2026 pp. 300-316 10.1182/blood.2025031683

Abstract Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a disorder caused by a mismatch in human platelet antigens (HPAs), leading to maternal antibody formation and platele...

Does epitope specificity dictate FNAIT severity?

Xun Grace Wu, Heyu Ni Jul 16, 2026 pp. 266-268 10.1182/blood.2026034152

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

Jennifer L. Crombie, Sairah Ahmed, Matthew J. Frigault et al. Jul 16, 2026 pp. 348-360 10.1182/blood.2025031733

Abstract This study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), inc...

Blinatumomab consolidation for high-risk Ph– B-ALL

Jul 16, 2026 pp. 390-390 10.1182/blood.2026035018

OutFOXing a FENDRR bender in T-ALL

Hansen J. Kosasih, Charles E. de Bock Jul 16, 2026 pp. 268-269 10.1182/blood.2026033890

Protein disulfide isomerase oxidase activity in thrombosis

Marie A. Hollenhorst Jul 16, 2026 pp. 273-274 10.1182/blood.2026033877

Chihara D, Dores GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. <i>Blood</i> . 2021;138(9):785-789.

Jul 16, 2026 pp. 389-389 10.1182/blood.2026035130

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page